Jefferies cuts Kinder Morgan stock price target on valuation refresh By Investing.com

Jefferies cut Kinder Morgan’s price target to $34 from $36 but kept a Hold rating after the company posted a strong Q1 2026 beat, with adjusted EBITDA up 10.2% versus Jefferies estimates and 10.6% above consensus. Management also signaled about 3% FY2026 EBITDA upside versus budget, while Jefferies raised its 2026 EBITDA estimate by 2.6% and nudged 2027+ estimates up 0.8% to 0.9% on the Monument purchase. Kinder Morgan also reported EPS of $0.48 versus $0.39 expected and revenue of $4.83 billion versus $4.63 billion consensus.

Analysis

The key read-through is not the modest estimate increase itself, but that management has created a short-cycle credibility catalyst in a sector where investors usually discount guidance until the next large FID is signed. If the market starts believing the early-year EBITDA run-rate is real, KMI can rerate from a "high-yield utility" multiple toward a premium midstream compounder multiple, which is where the upside comes from over the next 3-6 months rather than from incremental earnings alone.

The second-order winner is anyone levered to volume confirmation and project sanctioning, not just Kinder Morgan. A stronger balance sheet narrative and visible backlog conversion should tighten financing terms across midstream, while also pressuring competitors with weaker execution or higher leverage to compete harder for shipper commitments; that can delay or dilute capex returns elsewhere in the sector. The Monument-related uplift also matters because it suggests the market may be underestimating accretive tuck-ins in an industry where small basis-point changes in cost of capital can materially change project economics over a 2-3 year horizon.

The main risk is that this becomes a classic "good quarter, no new money" setup: if large FIDs slip by even one quarter, the stock can trade back to yield support rather than growth multiple expansion. That downside is more likely over the next 1-2 months than the next year, because the thesis is now tied to proof points on backlog conversion and capital deployment, not just operating performance. On the other hand, the sell-side revision wave is still early; if estimates continue moving up over the next 30-60 days, KMI could see incremental multiple compression risk for underexposed shorts rather than immediate downside for longs.

Contrarian view: consensus may be underpricing the durability of the beat if this is actually a higher-throughput, higher-contracting regime rather than a one-off quarter. The market is focused on whether management can close large projects, but the more important variable may be whether rising confidence lowers the perceived probability of execution misses across the entire funding cycle. That would make the stock less about next quarter and more about a multi-quarter de-risking of the franchise, which is exactly when midstream names can re-rate sharply.

Key Decisions for Investors

• Go long KMI for 3-6 months with a target of a multiple rerating rather than near-term earnings expansion; use a staged entry on any post-news consolidation, and risk-manage with a close below the prior support zone if project sanctioning rhetoric fades.
• Add a relative-value long KMI / short a higher-leverage midstream peer basket over 1-2 quarters; the cleaner balance sheet and improving credibility should outperform if capital markets stay selective.
• Sell out-of-the-money KMI calls 2-4 months out if implied vol remains elevated after the earnings move; the name has a tendency to digest good news before the next catalyst, improving premium capture versus outright upside.
• For event-driven accounts, buy a small KMI upside call spread into the next FID/backlog update; the payoff is asymmetric if management converts shadow backlog faster than consensus expects, but premium should be capped if the stock reverts to yield trading.